The IRA requires health plans serving the Part D market to cover all negotiated drugs, and it has been predicted that CMS ...

A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.

High consumption of ultra-processed foods elevates the risk of early-onset colorectal cancer, highlighting the need for ...

An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...

Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...

Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, ...

Jeff Schaffnit discusses Sanofi's advancements in BTK inhibitors and promising results for hemophilia A therapies at ASH 2025 ...

The use of an older medication at the time of surgery can reduce the need for red blood cell transfusions, according to a ...

A modified immunotherapy regimen for advanced melanoma showed a 49% response rate and extended median overall survival to 42 ...

Catheter ablation significantly reduces cardiovascular risks and mortality in patients with both atrial fibrillation and obstructive sleep apnea. The study involved over 18,000 patients, showing a ...

Clinicians are moving toward managing mild (Grade 1) cytokine release syndrome on an outpatient basis. The most common and ...

As the number of patients with multiple myeloma and lymphoma treated with CAR-T therapy increases, health systems are ...